United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 20

Name: Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 20 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderGeoVax · 43

Strongest available pathJourney Medical Corporation · -4.3%

Widest latest marginJourney Medical Corporation · -18.7%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GOVX · Nasdaq

GeoVax

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1988Smyrna, Georgia$3.2M market cap

View full Companies Radar profile

43Cautious

Snapshot price$0.61as of page date

Monthly-close return-100.0%five-year window

FY2024 revenue$0.00BGeoVax Labs, Inc.

Net margin-632.0%FY2024

Prism attention33.6%share across these five

Filing track recordRevenue, USD billions

+236.3%

FY2019–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 35.4%

52-week position0% through range

$0.59$19.20

News mentions919

Community mentions0partial coverage

U.S.-scope patents100

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal85/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2SGMT · Nasdaq

Sagimet Biosciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2007San Mateo, California$652.7M market cap

View full Companies Radar profile

43Cautious

Snapshot price$10.50as of page date

Monthly-close return-34.2%since July 2023

FY2024 revenue$0.00BSagimet Biosciences Inc.

Net margin-2278.3%FY2024

P/E snapshot-7.6xone ratio, not a verdict

Prism attention14.2%share across these five

Filing track recordRevenue, USD billions

+0.0%

FY2023–FY2024 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.0%

52-week position90% through range

$4.50$11.15

News mentions390

Community mentions0partial coverage

U.S.-scope patents46

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal47/100
Management stability90/100
Market position3/100
Capital-event signal59/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PRLD · Nasdaq

Prelude Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Philadelphia, Pennsylvania$437.3M market cap

View full Companies Radar profile

42Cautious

Snapshot price$5.49as of page date

Monthly-close return-82.4%five-year window

FY2025 revenue$0.01BPrelude Therapeutics Inc

Net margin-819.6%FY2025

P/E snapshot-7.3xone ratio, not a verdict

Prism attention13.3%share across these five

Filing track recordRevenue, USD billions

+73.4%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 73.4%

52-week position77% through range

$0.98$6.83

News mentions365

Community mentions4partial coverage

U.S.-scope patents311

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position7/100
Capital-event signal50/100
Innovation pulse9/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SCYX · Nasdaq

Scynexis

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Jersey City, New Jersey$51.4M market cap

View full Companies Radar profile

42Cautious

Snapshot price$5.17as of page date

Monthly-close return-87.8%five-year window

FY2025 revenue$0.02BSCYNEXIS INC

Net margin-41.8%FY2025

P/E snapshot-2.2xone ratio, not a verdict

Prism attention27.2%share across these five

Filing track recordRevenue, USD billions

+56.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 11.8%

52-week position24% through range

$3.53$10.48

News mentions746

Community mentions60partial coverage

U.S.-scope patents323

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal39/100
Management stability90/100
Market position8/100
Capital-event signal60/100
Innovation pulse9/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 2 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5DERM · Nasdaq

Journey Medical Corporation

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014Scottsdale, Arizona$213.7M market cap

View full Companies Radar profile

40Cautious

Snapshot price$7.57as of page date

Monthly-close return-4.3%five-year window

FY2025 revenue$0.06BJourney Medical Corp

Net margin-18.7%FY2025

Prism attention11.7%share across these five

Filing track recordRevenue, USD billions

-3.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.8%

52-week position62% through range

$4.31$9.55

News mentions321

Community mentions0partial coverage

U.S.-scope patents36

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Journey Medical Corporation

-4.3%

Sagimet Biosciences

-34.2%

Prelude Therapeutics

-82.4%

Scynexis

-87.8%

GeoVax

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Journey Medical Corporation

$0.06B

Scynexis

$0.02B

Prelude Therapeutics

$0.01B

GeoVax

$0.00B

Sagimet Biosciences

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Journey Medical Corporation

-18.7%

Scynexis

-41.8%

GeoVax

-632.0%

Prelude Therapeutics

-819.6%

Sagimet Biosciences

-2278.3%

Prism news attention

Normalized share across these five names; attention is not quality.

GeoVax

33.6%

Scynexis

27.2%

Sagimet Biosciences

14.2%

Prelude Therapeutics

13.3%

Journey Medical Corporation

11.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

GeoVax leads the conversation

It holds 33.6% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Journey Medical Corporation leads the available price paths

Its monthly-close return is -4.3% for the five-year window. At the other end, GeoVax is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Journey Medical Corporation has the widest latest margin

Its FY2025 net margin is -18.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Sagimet Biosciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -7.6x while its since July 2023 price return is -34.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GOVX

GeoVax

919available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+43.4%218 latest 12m vs 152 prior 12m

Machine-classified coverage tone

87.7% positive-5.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

vaccine trials 54vaccine candidates 53vaccine immunogenicity 46vaccine formulation 39investigational new vaccine 37vaccination campaigns 30viral vector vaccines 30vaccine preclinical testing 29

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-06–2026-06-03 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SCYX

Scynexis

60 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 60 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GOVX

GeoVax

through 2026-04-15

Company announcements 6Earnings releases 6Listing / IPO 1

2026-04-15
Earnings releases
The company reported $1.85 earnings per share (EPS) for the quarter.
2026-02-13
Listing / IPO
GeoVax Labs, Inc., a clinical-stage biotechnology company, announced it has entered into definitive agreements for a registered direct offering priced at-the-market under Nasdaq rules.
2026-01-20
Company announcements
GeoVax Labs, Inc., a clinical-stage biotechnology company, has outlined 2026 as a pivotal inflection year driven by multiple late-stage clinical, regulatory, and manufacturing milestones across its diversified portfolio of vaccines and immunotherapies.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SGMT

Sagimet Biosciences

through 2025-12-10

Leadership changes 11Earnings releases 6Listing / IPO 5Company announcements 4Asset acquisitions 1

2025-12-10
Company announcements
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet’s Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company’s Series A common stock as determined based on the Black Scholes value on December 9, 2025, to be granted on December 9, 2025 to the three newly-hired employees.
2025-07-28
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sagimet Biosciences $2.00 million 157.03 -$45.57 million ($1.76) -5.82
2024-08-01
Leadership changes
Sagimet Biosciences Inc. has expanded its Board of Directors, appointing Jennifer Jarrett and Dr. Anne Phillips, bringing extensive experience from their previous roles in biopharmaceutical companies and other healthcare-related industries.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRLD

Prelude Therapeutics

through 2025-11-12

Company announcements 5Leadership changes 5Earnings releases 4Business contracts 1

2025-11-12
Earnings releases
(UNAUDITED) Three Months Ended September 30, (in thousands, except share and per share data) 2025 2024 Revenue $ 6,500 $ 3,000 Operating expenses Research and development 21,708 29,457 General and administrative 5,210 7,919 Total operating expenses 26,918 37,376 Loss from operations (20,418 ) (34,376 ) Other income, net 693 2,105 Net loss $ (19,725 ) $ (32,271 ) Per share information: Net loss per share of common stock, basic and diluted $ (0.26 ) $ (0.43 )
2025-11-04
Company announcements
JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised
2025-11-04
Business contracts
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program, including Prelude’s library of preclinical candidates.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SCYX

Scynexis

through 2025-11-06

Business contracts 6Earnings releases 6Company announcements 5Listing / IPO 2Lawsuits 1

2025-11-06
Company announcements
JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2025.
2025-03-12
Earnings releases
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines ... today reported financial results for the year ended December 31, 2024.
2025-02-14
Regulatory
cleared by the U.S. FDA for vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DERM

Journey Medical Corporation

through 2026-03-27

Earnings releases 25Leadership changes 4Company announcements 3

2026-03-27
Earnings releases
Full‑year 2025 revenue was $61.9M (+10%), gross margin improved to 66.2%, GAAP net loss narrowed to $11.4M, and the company reported positive adjusted EBITDA of $2.9M while ending the year with ~$24.1M cash.
2025-08-07
Company announcements
today announced that the management team of Journey Medical will ring the closing bell at the Nasdaq MarketSite in Times Square on Monday, August 11, 2025 at 4:00 p.m. ET.
2025-04-01
Leadership changes
Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 96–103. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

GeoVax leads the readiness ranking

Its Prism readiness score is 43/100, the highest in this five-company comparison.

Open GeoVax in Companies Radar

Scale and margin leadership sit with Journey Medical Corporation and Journey Medical Corporation

Journey Medical Corporation has the largest displayed latest revenue at $0.06B; Journey Medical Corporation has the widest displayed latest margin at -18.7%.

Open Journey Medical Corporation in Companies Radar

Comparisons

Strongest versus weakest available price path

Journey Medical Corporation is -4.3% for its five-year window; GeoVax is -100.0% for its five-year window.

Open Journey Medical Corporation in Companies Radar Open GeoVax in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.06B for Journey Medical Corporation to $0.00B for Sagimet Biosciences. Entity and filing-period labels remain visible on the company cards.

Open Journey Medical Corporation in Companies Radar Open Sagimet Biosciences in Companies Radar

Anomalies

Scynexis has the widest attention-readiness rank gap

It ranks #2 by measured news attention (27.2%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Scynexis in Companies Radar

GeoVax shows a price-operating divergence to inspect

Its displayed filing-revenue change is +236.3% while its available monthly-close return is -100.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open GeoVax in Companies Radar

Explanations

Attention measures coverage volume, not quality

GeoVax's 33.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open GeoVax in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open GeoVax's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 43/100 score.

Open GeoVax in Companies Radar

Stress-test the largest divergence before forming a view

Compare GeoVax's profile with Journey Medical Corporation's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open GeoVax in Companies Radar Open Journey Medical Corporation in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.